44
Participants
Start Date
October 31, 2007
Primary Completion Date
March 31, 2010
Study Completion Date
December 31, 2010
nimotuzumab (anti EGFR humanized monoclonal antibody)
150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
NYU Medical Center, Hassenfeld Clinic, New York
University of Rochester Medical Center, Strong Memorial Hospital, Rochester
Memorial Sloan-Kettering Cancer Center, New York
Children's National Medical Center, Washington D.C.
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore
University of Florida Shands Cancer Center, Gainesville
The Chaim Sheba Medical Center, Tel Litwinsky
The University of Texas/M.D. Anderson Cancer Center, Houston
Children's Hospital/University of Colorado, Denver
Children's Memorial Hospital, Chicago
Vanderbilt University Medical Center, Nashville
Alberta Children's Hospital, Calgary
The Hospital For Sick Children, Toronto
Lead Sponsor
YM BioSciences
INDUSTRY